Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023473 (
chronic myeloid leukemia
)
18,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
T315I Bcr-Abl in
chronic myelogenous leukemia
(
CML
) is the most notorious point mutations to elicit acquired resistance to imatinib. In the present study, we investigated the effect of celastrol on
CML
cells bearing wild-type Bcr-Abl or T315I-mutant. The results revealed that celastrol potently downregulated the protein levels of Bcr-Abl, and inhibited the growth in
CML
cells in vitro and in nude mouse xenografts regardless of Bcr-Abl mutation status.
Celastrol
induced mitochondrial-dependent apoptosis. In conclusion, celastrol exhibits potent activity against
CML
cells bearing wild-type Bcr-Abl or -the T315I-mutant.
...
PMID:Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation. 1981 19
